ClimAIr: AI to Assess the Impact of Pollution and Climate on Respiratory Health in Europe

Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study ID
NCT07107009
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The ClimAIr project will expand the evidence-based understanding of climate change, air pollution, and non-communicable respiratory diseases by using Artificial Intelligence (AI) tools. It will gather data on greenhouse gases levels and disaster risks, information on serious air pollutants and respiratory diseases' prevalence. The AI powered tools will be employed to generate better intervention methods and improve public health outcomes. Federated Learning (FL) will be used to develop AI models to protect patients' privacy. By raising public awareness and delivering the ClimAIr tool - specifically designed to health workers, urban planners and policy makers - the project aims to influence policy decisions, promote healthier environments, and reduce respiratory diseases in Europe, which will be tested and validated the ClimAIr tool in specific municipalities that are part of the project. ClimAIr draws on a consortium of 21 partners from 15 European countries, including carefully selected health centres across Europe - in Spain, Luxembourg, Ukraine, Italy, France, Germany, Greece, Romania and Poland - focused on respiratory diseases, which will provide disease data and explore metabolic routes of the studied contaminants/diseases. ClimAIr is composed of an interdisciplinary team formed by research centres, ethical AI and modelling experts, SSH specialists, municipal governance, and a Communication \& Dissemination (C\&D) expert team dedicated to achieving and spread the results of the project.

Key Dates

First listed
Aug 6, 2025
Start date
Jan 31, 2026
Status verified
Dec 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
1,906 participants (estimated)

Arms

  • Arm: P01 - General Exposure Cohort
    \>200 AR patients per environmental condition. Includes patients exposed to various air pollutants, aiming to detect deleterious clinical effects.
  • Arm: P02 - Omics Synergistic Subgroup
    Subgroup of 20 patients per environmental condition from P01. Selected based on exposure to multiple pollutants with observed synergistic effects on omics parameters.
  • Arm: S01 - Allergen-Specific Immune Response Subgroup
    Subgroup of 25 patients per pollution condition from P01. Selected for in vitro assays to evaluate proliferation of peripheral allergen-specific lymphocytes in response to polluted pollen exposure.

Primary Outcome Measure

Mean Symptom Score of Allergic Rhinitis Patients by Environmental Exposure [ Time Frame: Retrospective data collected over a 3-year period prior to study enrollment. ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies